Director of Pharmacy Minnesota Oncology Mayo Clinic College of Medicine North Oaks, Minnesota
It can be challenging for clinicians to determine the most appropriate therapeutic approach for multiple myeloma (MM), especially since most patients experience relapse and adverse events. This session will highlight how specialty pharmacists can help optimize outcomes for individuals with relapsed/refractory MM (RRMM) while managing toxicities associated with treatment. The efficacy/safety and mechanisms of action of novel targeted RRMM therapies will be discussed.
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics.